Skip to contentF
Filana Therapeutics, Inc.
F
FLNAFilana Therapeutics, Inc. Q3 2016 · 10-Q
Revenue—
Net Income-$3.52M-$3.52MN/M vs Q3 2015 EPS Diluted-$0.54-$0.54N/M vs Q3 2015 Operating Income-$3,541,000N/M Operating Cash Flowderived-$2,787,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Filana Therapeutics, Inc. · CIK 1069530 · Engraved from SEC EDGAR
ended Sep 30, 2016 · filed Oct 26, 2016 · 26 d after period end